Synthetic lethal metabolic targeting of cellular senescence in cancer therapy

@article{Drr2013SyntheticLM,
  title={Synthetic lethal metabolic targeting of cellular senescence in cancer therapy},
  author={J. D{\"o}rr and Yong Yu and M. Milanovic and Gregor Beuster and C. Zasada and J. D{\"a}britz and J. Lisec and D. Lenze and A. Gerhardt and K. Schleicher and S. Kratzat and B. Purf{\"u}rst and S. Walenta and W. Mueller-Klieser and M. Gr{\"a}ler and M. Hummel and U. Keller and A. Buck and B. Dörken and L. Willmitzer and M. Reimann and S. Kempa and Soyoung Lee and C. Schmitt},
  journal={Nature},
  year={2013},
  volume={501},
  pages={421-425}
}
Activated oncogenes and anticancer chemotherapy induce cellular senescence, a terminal growth arrest of viable cells characterized by S-phase entry-blocking histone 3 lysine 9 trimethylation (H3K9me3). Although therapy-induced senescence (TIS) improves long-term outcomes, potentially harmful properties of senescent tumour cells make their quantitative elimination a therapeutic priority. Here we use the Eµ-myc transgenic mouse lymphoma model in which TIS depends on the H3K9 histone… Expand
Senescence-associated reprogramming promotes cancer stemness
Selective elimination of senescent cells by mitochondrial targeting is regulated by ANT2
Genotoxic Stress-Induced Senescence.
Bafilomycin A1 triggers proliferative potential of senescent cancer cells in vitro and in NOD/SCID mice
Dynamic Metabolic Response to Adriamycin-Induced Senescence in Breast Cancer Cells
Cellular Senescence Promotes Adverse Effects of Chemotherapy and Cancer Relapse.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 58 REFERENCES
...
1
2
3
4
5
...